TY - JOUR
T1 - The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases
AU - Pant, Kishor
AU - Venugopal, Senthil K.
AU - Lorenzo Pisarello, Maria J.
AU - Gradilone, Sergio A.
N1 - Publisher Copyright:
© 2023 American Society for Investigative Pathology
PY - 2023/10
Y1 - 2023/10
N2 - The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases.
AB - The short-chain fatty acid butyrate, produced from fermentable carbohydrates by gut microbiota in the colon, has multiple beneficial effects on human health. At the intestinal level, butyrate regulates metabolism, helps in the transepithelial transport of fluids, inhibits inflammation, and induces the epithelial defense barrier. The liver receives a large amount of short-chain fatty acids via the blood flowing from the gut via the portal vein. Butyrate helps prevent nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, inflammation, cancer, and liver injuries. It ameliorates metabolic diseases, including insulin resistance and obesity, and plays a direct role in preventing fatty liver diseases. Butyrate has different mechanisms of action, including strong regulatory effects on the expression of many genes by inhibiting the histone deacetylases and modulating cellular metabolism. The present review highlights the wide range of beneficial therapeutic and unfavorable adverse effects of butyrate, with a high potential for clinically important uses in several liver diseases.
UR - http://www.scopus.com/inward/record.url?scp=85171441845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85171441845&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2023.06.007
DO - 10.1016/j.ajpath.2023.06.007
M3 - Review article
C2 - 37422149
AN - SCOPUS:85171441845
SN - 0002-9440
VL - 193
SP - 1455
EP - 1467
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 10
ER -